Barclays sees European chemicals at peak cycle; upgrades Wacker, Solvay, cuts Clariant

By Reuters News

** Barclays says chemicals are around their peak cycle with fundamentals set to weaken through 2027, although Middle East disruption has supported pricing

** It sees supply tightness supporting earnings through Q4 and into Q1 2027, delaying rather than preventing the downturn, with more caution from Q2, as companies "begin to lap stronger volume comparatives and tougher comparatives from the onset of the conflict"

** Q3 was a pricing quarter rather than a volume quarter, the broker says, with pricing accelerating from -2% yoy in Q1 to +7% in Q3 and beating expectations across most diversified chemicals, while volumes generally slowed versus Q2

** Barclays raises Solvay SOLB.BR to "equal weight" from "underweight" and its PT to €24 from €20, citing potential OneIM rare-earths JV with gross cash proceeds which could reduce leverage, stopping "short of 'overweight' given continued FCF/dividend risk"

** The broker raises Wacker Chemie WCHG.DE to "overweight" from "equal weight", as it believes that FY 2027 expectations, asymmetric polysilicon optionality and EU silicones tailwind create an attractive setup

** It however cuts Clariant CLN.S to "equal weight" from "overweight", on renewed litigation risk not reflected in the shares, questioning FY 2027 expectations and Ashland deal risks

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.